CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group
Cameron, D.A.; White, J.M.; Proctor, S.J.; Prescott, R.J.; Leonard, R.C.; Angus, B.; Cook, M.K.; Dawes, P.J.; Dawson, A.A.; Evans, R.G.; Galloway, M.J.; Harris, A.L.; Heppleston, A.; Horne, C.H.; Krajewski, A.S.; Lennard, A.L.; Lessells, A.M.; Lucraft, H.H.; MacGillivray, J.B.; Mackie, M.J.; Parker, A.C.; Roberts, J.T.; Taylor, P.R.; Thompson, W.D.
European Journal of Cancer 33(8): 1195-1201
1997
ISSN/ISBN: 0959-8049
PMID: 9301442
DOI: 10.1016/s0959-8049(97)00051-8
Accession: 045417310
The aim of this study was to test whether survival for patients with high-grade non-Hodgkin's lymphoma (NHL) can be improved with a non-cross-resistant regimen as compared to a CHOP-based regimen. This is a multicentre study comprising 325 adult patients, median age 58 years, with high-grade non-Hodgkin's lymphoma: patients of any age and performance status were eligible provided they were able to receive the drugs in the regimens. Patients were randomised to either B-CHOP-M (bleomycin, cyclophosphamide, doxorubicin, vincristine, prednisolone and methotrexate) or PEEC-M (methylprednisolone, vindesine, etoposide, chlorambucil and methotrexate) alternating with B-CHOP-M. At a median follow-up of 9 years, there was no significant difference in overall survival or disease-free survival between the two arms. Toxicities for the two regimens were equivalent. This study confirms that for relatively unselected patients with high-grade non-Hodgkin's lymphoma, an alternating multidrug regimen does not improve upon the results obtained with B-CHOP-M.